Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
- PMID: 9462579
- DOI: 10.1016/s0735-1097(97)00510-x
Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease
Abstract
Objectives: We sought to examine whether patients with stable coronary artery disease (CAD) have increased platelet reactivity and an enhanced propensity to form monocyte-platelet aggregates.
Background: Platelet-dependent thrombosis and leukocyte infiltration into the vessel wall are characteristic cellular events seen in atherosclerosis.
Methods: Anticoagulated peripheral venous blood from 19 patients with stable CAD and 19 normal control subjects was incubated with or without various platelet agonists and analyzed by whole blood flow cytometry.
Results: Circulating degranulated platelets were increased in patients with CAD compared with control subjects (mean [+/- SEM] percent P-selectin-positive platelets: 2.1 +/- 0.2 vs. 1.5 +/- 0.2, p < 0.01) and were more reactive to stimulation with 1 micromol/liter of adenosine diphosphate (ADP) (28.7 +/- 3.9 vs. 16.1 +/- 2.2, p < 0.01), 1 micromol/liter of ADP/epinephrine (51.4 +/- 4.6 vs. 37.5 +/- 3.8, p < 0.05) or 5 micromol/liter of thrombin receptor agonist peptide (TRAP) (65.7 +/- 6.8 vs. 20.2 +/- 5.1, p < 0.01). Patients with stable CAD also had increased circulating monocyte-platelet aggregates compared with control subjects (percent platelet-positive monocytes: 15.3 +/- 3.0 vs. 6.3 +/- 0.9, p < 0.01). Furthermore, patients with stable CAD formed more monocyte-platelet aggregates than did control subjects when their whole blood was stimulated with 1 micromol/liter of ADP (50.4 +/- 4.5 vs. 28.1 +/- 5.3, p < 0.01), 1 micromol/liter of ADP/epinephrine (60.7 +/- 4.3 vs. 48.0 +/- 4.8, p < 0.05) or 5 micromol/liter of TRAP (67.6 +/- 5.7 vs. 34.3 +/- 7.0, p < 0.01).
Conclusions: Patients with stable CAD have circulating activated platelets, circulating monocyte-platelet aggregates, increased platelet reactivity and an increased propensity to form monocyte-platelet aggregates.
Similar articles
-
Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count.Eur J Haematol. 2001 Mar;66(3):143-51. doi: 10.1034/j.1600-0609.2001.00359.x. Eur J Haematol. 2001. PMID: 11350482
-
Dynamics of leukocyte-platelet adhesion in whole blood.Blood. 1991 Oct 1;78(7):1730-7. Blood. 1991. PMID: 1717069
-
Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty.Atherosclerosis. 2014 Jan;232(1):119-24. doi: 10.1016/j.atherosclerosis.2013.10.027. Epub 2013 Nov 10. Atherosclerosis. 2014. PMID: 24401225
-
Platelet in progression of atherosclerosis: a potential target in diabetic patients.Curr Diabetes Rev. 2005 May;1(2):159-65. doi: 10.2174/1573399054022758. Curr Diabetes Rev. 2005. PMID: 18220591 Review.
-
The biology of thrombin in acute coronary syndromes.Pharmacotherapy. 2002 Jun;22(6 Pt 2):90S-96S. doi: 10.1592/phco.22.10.90s.33617. Pharmacotherapy. 2002. PMID: 12064570 Review.
Cited by
-
Monocyte Single-Cell Multimodal Profiling in Cardiovascular Disease Risk States.Circ Res. 2024 Aug 30;135(6):685-700. doi: 10.1161/CIRCRESAHA.124.324457. Epub 2024 Aug 6. Circ Res. 2024. PMID: 39105287
-
Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin.Heart. 2006 Nov;92(11):1635-8. doi: 10.1136/hrt.2005.063917. Epub 2006 May 18. Heart. 2006. PMID: 16709700 Free PMC article.
-
Neutrophil-Platelet Interactions as Novel Treatment Targets in Cardiovascular Disease.Front Cardiovasc Med. 2022 Jan 31;8:824112. doi: 10.3389/fcvm.2021.824112. eCollection 2021. Front Cardiovasc Med. 2022. PMID: 35174225 Free PMC article. Review.
-
The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1.J Exp Med. 2002 Sep 2;196(5):679-91. doi: 10.1084/jem.20020267. J Exp Med. 2002. PMID: 12208882 Free PMC article.
-
Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.Infect Immun. 2005 Dec;73(12):8306-16. doi: 10.1128/IAI.73.12.8306-8316.2005. Infect Immun. 2005. PMID: 16299328 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous